Daclatasvir Dihydrochloride Intermediate CAS 1007882-23-6 Purity >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Daclatasvir Dihydrochloride Intermediate (CAS: 1007882-23-6) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, small and bulk quantities available. Purchase Daclatasvir Dihydrochloride Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidinecarboxylate) |
| Synonyms | Daclatasvir Intermediate Ⅱ; Dacaltasvir Intermediate 02; Daclatasvir T-Butyl Ester; Bis(2-Methyl-2-Propanyl) (2S,2'S)-2,2'-[4,4'-Biphenyldiylbis(1H-Imidazole-4,2-diyl)]di(1-Pyrrolidinecarboxylate); Di-tert-butyl 2,2′-([1,1′-Biphenyl]-4,4′-diylbis(1H-Imidazole-5,2-diyl))(2S,2’S)-bis(Pyridineidine-1-Carboxylate); (2S,2’S)-2,2’-([1,1’-Biphenyl]-4,4’-diyldi-1H-Imidazole-5,2-diyl)bis-1-Pyrrolidinecarboxylic Acid 1,1’-Bis(1,1-Dimethylethyl) Ester; Daclatasvir Impurity 4 |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 1007882-23-6 |
| Molecular Formula | C40H51ClN8O6 |
| Molecular Weight | 775.35 g/mol |
| Boiling Point | 890.2±65.0℃ at 760 mmHg |
| Density | 1.220±0.06 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6) |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | Light Yellow to Yellow Powder |
Light Yellow Powder |
| Loss on Drying | <1.00% | 0.65% |
| Maximum Single Impurity | <1.00% | 0.45% |
| Total Impurities | <2.00% | 1.24% |
| Purity / Analysis Method | >98.0% (HPLC) | 98.76% |
| Infrared Spectrum | Consistent with Structure | Complies |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6) | |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidinecarboxylate) (CAS: 1007882-23-6) is an intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6).
Daclatasvir (Daklinza) has obtained "priority review" status, combined with Sorafenib for the treatment of genotype III adult patients with chronic hepatitis C. Daklinza has been the first drug that has been proved of being effective in the treatment of genotype III hepatitis C virus infection without the co-administration with interferon or ribavirin. Interferon and Ribavirin are two drugs approved by FDA for the treatment of hepatitis C virus infection. Hepatitis C is a viral disease that can cause inflammation of the liver, resulting in decreased liver function or liver failure. Most patients infected with hepatitis C have no symptoms until liver damage becomes apparent, which may take several years. Globally, genotype III hepatitis C is the second most common genotype of hepatitis C after genotype 1 hepatitis C and is considered to be one of the most refractory genotype diseases. Daklinza is a pan-genotype NS5A replication complex inhibitor, with efficacy of inhibition of RNA replication and viral assembly, dual antiviral effect. For in vitro studies, Daklinza has been demonstrated to have anti-viral effect against genotype 1~6 hepatitis C virus. Daklinza is accompanied by a warning that the combination of amiodarone, Daklinza and Sofosbuvir may cause severe reduced heart rate. Daklinza is an oral tablet with the recommended dose of 60 mg for 1 times/d, in conjunction with Sofosbuvir for a total of 12 weeks.
Research and development company: Bristol-Myers Squibb.
Patent Literature: WO 2008021927A2 (August 9, 2007).
Time of marketing: July 24, 2015 listed in the United States, trade name Daklinza.
Indications: Used in combination with Sofosbuvir for the treatment of genotype 3 chronic hepatitis C (HCV) infection.
Mechanism of action: HCV nonstructural protein 5A (NS5A) inhibitors. Adverse reactions: headaches and fatigue.
Formulation and specifications: Tablets, 30 and 60mg.
